The FDA shut down the genetic company's sales of personalized health reports, but CEO Anne Wojcicki is working to get that part of her business back up and running.
The Wall Street Journal: Anne Wojcicki's Quest For Better Health Care
Anne Wojcicki, chief executive of 23andMe, is determined to overturn the way traditional health care works in the U.S. It hasn't been easy. Last year, the Food and Drug Administration shut down sales of her genetics company's personalized health reports -- one of its main sources of revenue. But Ms. Wojcicki (pronounced wo-JIT-ski) isn't backing down. ... Her company is working with the FDA on getting its reports approved for direct delivery to consumers. Before the FDA's warning letter, 23andMe had 550,000 customers. Now it has 700,000, though growth has slowed (Wolfe, 6/27).
The Washington Post: 23andMe Co-Founder Anne Wojcicki’s Washington Charm Offensive
In early May, Anne Wojcicki flew into Washington accompanied by two other billionaire Silicon Valley wives intent on shaking up the health-care industry. Her genetic profiling start-up, 23andMe, a darling of the tech industry, had recently run into trouble with the Food and Drug Administration. It was a setback for the company, but it had given her an important lesson in the power of government. ... It was Wojcicki’s first time at the soiree, a coming out for her on the political scene, and she had a lot to say. The first is that the U.S. health-care system is broken (Cha, 6/27).